In a significant move for Replimune Group, Inc. (ticker: REPL), analyst Robert Burns of HC Wainwright & Co. upgraded the company to a “Buy” on October 27, 2025, setting a price target of $12. This ...
Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
As a Full-Stack Developer with a testing mindset, you will support the development and quality assurance of our SaaS platform. Responsibilities include: Write, maintain, and optimize automated test ...
Nuno will take charge of his new side for the first time at Hill Dickinson Stadium after replacing Graham Potter on Saturday. The former Nottingham Forest boss has penned a three-year deal with the ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
Hosted on MSN
JP Morgan Downgrades Replimune Group (REPL)
Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback